

Jerome H Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7401583/publications.pdf>

Version: 2024-02-01

127
papers

16,118
citations

41258

49
h-index

16605

123
g-index

132
all docs

132
docs citations

132
times ranked

11494
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. <i>New England Journal of Medicine</i> , 2009, 361, 2209-2220.	13.9	2,748
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	13.9	1,699
3	Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. <i>Nature</i> , 2014, 512, 74-77.	13.7	527
4	Looking beyond COVID-19 vaccine phase 3 trials. <i>Nature Medicine</i> , 2021, 27, 205-211.	15.2	473
5	Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. <i>Nature</i> , 2012, 482, 89-93.	13.7	452
6	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	5.8	412
7	Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. <i>Nature</i> , 2012, 490, 417-420.	13.7	405
8	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
9	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	3.3	371
10	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. <i>Science Translational Medicine</i> , 2014, 6, 228ra38.	5.8	367
11	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	1.5	357
12	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	13.5	334
13	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	13.5	326
14	Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. <i>PLoS ONE</i> , 2012, 7, e33948.	1.1	276
15	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	1.9	273
16	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018, 24, 923-926.	15.2	263
17	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	1.1	248
18	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287.	13.7	246

#	ARTICLE	IF	CITATIONS
19	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	9.4	232
20	Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. <i>New England Journal of Medicine</i> , 2016, 374, 2120-2130.	13.9	229
21	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , 2011, 17, 366-371.	15.2	220
22	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. <i>PLoS Pathogens</i> , 2014, 10, e1004543.	2.1	218
23	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	1.1	214
24	Vaccine development for emerging infectious diseases. <i>Nature Medicine</i> , 2021, 27, 591-600.	15.2	213
25	Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 531-537.	4.6	201
26	Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies. <i>Journal of Virology</i> , 2014, 88, 12385-12396.	1.5	198
27	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	15.2	197
28	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	0.5	191
29	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	1.5	169
30	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	1.1	165
31	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. <i>Annual Review of Medicine</i> , 2015, 66, 423-437.	5.0	150
32	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV _{mac251} Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	1.5	130
33	The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics. <i>Clinical Infectious Diseases</i> , 2019, 69, 877-883.	2.9	122
34	The global burden and epidemiology of invasive non-typhoidal <i>Salmonella</i> infections. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1421-1426.	1.4	118
35	Nonneutralizing Functional Antibodies: a New Paradigm for HIV Vaccines. <i>Vaccine Journal</i> , 2014, 21, 1023-1036.	3.2	107
36	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. <i>Lancet</i> , The, 2021, 397, 562-564.	6.3	105

#	ARTICLE	IF	CITATIONS
37	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	95
38	A novel acute HIV infection staging system based on 4th generation immunoassay. <i>Retrovirology</i> , 2013, 10, 56.	0.9	93
39	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	73
40	Operation Warp Speed: implications for global vaccine security. <i>The Lancet Global Health</i> , 2021, 9, e1017-e1021.	2.9	72
41	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	69
42	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	6.6	65
43	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	2.1	63
44	Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. <i>Expert Review of Vaccines</i> , 2010, 9, 1055-1069.	2.0	62
45	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	1.5	59
46	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	1.9	57
47	Current and future cholera vaccines. <i>Vaccine</i> , 2020, 38, A118-A126.	1.7	57
48	Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. <i>Journal of Infectious Diseases</i> , 2013, 207, 1195-1205.	1.9	56
49	Impact of early cART in the gut during acute HIV infection. <i>JCI Insight</i> , 2016, 1, .	2.3	56
50	The Euvichol story – Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. <i>Vaccine</i> , 2018, 36, 6606-6614.	1.7	56
51	Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. <i>EBioMedicine</i> , 2014, 1, 37-45.	2.7	55
52	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	1.1	55
53	T cell-oriented strategies for controlling the COVID-19 pandemic. <i>Nature Reviews Immunology</i> , 2021, 21, 687-688.	10.6	54
54	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. <i>Journal of Clinical Investigation</i> , 2019, 129, 3361-3373.	3.9	54

#	ARTICLE	IF	CITATIONS
55	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	1.5	51
56	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.3	50
57	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	15.2	50
58	Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13439-13444.	3.3	49
59	Acute HIV infection detection and immediate treatment estimated to reduce transmission by 89% among men who have sex with men in Bangkok. <i>Journal of the International AIDS Society</i> , 2017, 20, 21708.	1.2	48
60	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	1.5	45
61	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2021, 39, 101053.	3.2	45
62	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	45
63	Review on the Recent Advances on Typhoid Vaccine Development and Challenges Ahead. <i>Clinical Infectious Diseases</i> , 2020, 71, S141-S150.	2.9	41
64	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to $\alpha 4\beta 7$ Integrin Receptor. <i>PLoS ONE</i> , 2015, 10, e0143895.	1.1	41
65	Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens. <i>PLoS ONE</i> , 2012, 7, e45840.	1.1	40
66	Distinct gene-expression profiles associated with the susceptibility of pathogen-specific CD4 T cells to HIV-1 infection. <i>Blood</i> , 2013, 121, 1136-1144.	0.6	38
67	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 410-423.	0.5	38
68	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	2.1	38
69	Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children. <i>Vaccine</i> , 2018, 36, 3794-3801.	1.7	36
70	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.3	36
71	Current approaches to HIV vaccine development: a narrative review. <i>Journal of the International AIDS Society</i> , 2021, 24, e25793.	1.2	35
72	Novel prime-boost vaccine strategies against HIV-1. <i>Expert Review of Vaccines</i> , 2019, 18, 765-779.	2.0	34

#	ARTICLE	IF	CITATIONS
73	Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. <i>Journal of Medical Virology</i> , 2022, 94, 1085-1095.	2.5	34
74	Cryptic Determinant of $\hat{I}\pm 4\hat{I}^27$ Binding in the V2 Loop of HIV-1 gp120. <i>PLoS ONE</i> , 2014, 9, e108446.	1.1	33
75	Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16 \hat{a} €“STING \hat{a} €“Type I IFN Pathway and AIM2 Sensor. <i>Journal of Immunology</i> , 2017, 199, 3293-3305.	0.4	33
76	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	2.1	33
77	Neglecting the neglected: the objective evidence of underfunding in rheumatic heart disease. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 287-290.	0.7	31
78	HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1734-1746.	1.4	30
79	HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1060-1076.	0.5	29
80	Prospects for a globally effective HIV-1 vaccine. <i>Vaccine</i> , 2015, 33, D4-D12.	1.7	28
81	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 807-816.	0.5	27
82	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	5.8	27
83	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27
84	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	2.1	26
85	Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. <i>Journal of Virology</i> , 2016, 90, 4005-4016.	1.5	25
86	Supply and delivery of vaccines for global health. <i>Current Opinion in Immunology</i> , 2021, 71, 13-20.	2.4	25
87	Sequential Dysfunction and Progressive Depletion of <i>Candida albicans</i> -Specific CD4 T Cell Response in HIV-1 Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005663.	2.1	25
88	Molecular dating and viral load growth rates suggested that the eclipse phase lasted about a week in HIV-1 infected adults in East Africa and Thailand. <i>PLoS Pathogens</i> , 2020, 16, e1008179.	2.1	24
89	The epidemiology of dengue outbreaks in 2016 and 2017 in Ouagadougou, Burkina Faso. <i>Heliyon</i> , 2020, 6, e04389.	1.4	23
90	Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte \hat{a} €“derived macrophages: the importance of HIV-1 envelope V1V2 region. <i>Journal of Leukocyte Biology</i> , 2016, 99, 1089-1106.	1.5	19

#	ARTICLE	IF	CITATIONS
91	Vaccination against SARS-CoV-2 and disease enhancement “knowns and unknowns. Expert Review of Vaccines, 2020, 19, 691-698.	2.0	19
92	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. Journal of Virology, 2020, 94, .	1.5	19
93	HIV vaccine delayed boosting increases Env variable region 2“specific antibody effector functions. JCI Insight, 2020, 5, .	2.3	18
94	HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults. AIDS Research and Human Retroviruses, 2014, 30, A33-A34.	0.5	17
95	Accelerating the development of a group A <i>Streptococcus</i> vaccine: an urgent public health need. Clinical and Experimental Vaccine Research, 2016, 5, 101.	1.1	16
96	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. Cells, 2019, 8, 902.	1.8	15
97	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. Immunogenetics, 2014, 66, 299-310.	1.2	14
98	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS ONE, 2018, 13, e0196397.	1.1	14
99	Immunogenicity, safety and reactogenicity of a Phase II trial of Vi-DT typhoid conjugate vaccine in healthy Filipino infants and toddlers: A preliminary report. Vaccine, 2020, 38, 4476-4483.	1.7	14
100	Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study. EClinicalMedicine, 2020, 27, 100540.	3.2	14
101	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. EBioMedicine, 2015, 2, 713-722.	2.7	13
102	First clinical trial of a MERS coronavirus DNA vaccine. Lancet Infectious Diseases, The, 2019, 19, 924-925.	4.6	13
103	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	2.1	13
104	Impact of HIV-1 Backbone on Neutralization Sensitivity: Neutralization Profiles of Heterologous Envelope Glycoproteins Expressed in Native Subtype C and CRF01_AE Backbone. PLoS ONE, 2013, 8, e76104.	1.1	12
105	An overview of Vaxchora TM , a live attenuated oral cholera vaccine. Human Vaccines and Immunotherapeutics, 2020, 16, 42-50.	1.4	12
106	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. JCI Insight, 2020, 5, .	2.3	12
107	HIV-specific Antibody in Rectal Secretions Following Late Boosts in RV144 Participants (RV305). AIDS Research and Human Retroviruses, 2014, 30, A33-A33.	0.5	11
108	Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease. Clinical Infectious Diseases, 2018, 67, 1824-1830.	2.9	11

#	ARTICLE	IF	CITATIONS
109	Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. <i>Vaccine</i> , 2017, 35, 1184-1193.	1.7	9
110	SARS-CoV-2 vaccine development, access, and equity. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	9
111	HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response. <i>Expert Review of Vaccines</i> , 2016, 15, 709-717.	2.0	7
112	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
113	Next-generation sequencing of HIV-1 single genome amplicons. <i>Biomolecular Detection and Quantification</i> , 2019, 17, 100080.	7.0	7
114	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. <i>PLoS Medicine</i> , 2021, 18, e1003772.	3.9	7
115	Nautilus: A Bioinformatics Package for the Analysis of HIV Type 1 Targeted Deep Sequencing Data. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1361-1364.	0.5	6
116	Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1036-1037.	1.4	6
117	Targeted deep sequencing of HIV-1 using the IonTorrentPGM platform. <i>Journal of Virological Methods</i> , 2014, 205, 7-16.	1.0	5
118	Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2149-2157.	1.4	5
119	Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 760-761.	4.6	4
120	Factors influencing estimates of HIV-1 infection timing using BEAST. <i>PLoS Computational Biology</i> , 2021, 17, e1008537.	1.5	4
121	Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes.. <i>Journal of Virological Methods</i> , 2016, 230, 45-52.	1.0	3
122	Geographical distribution of risk factors for invasive non-typhoidal Salmonella at the subnational boundary level in sub-Saharan Africa. <i>BMC Infectious Diseases</i> , 2021, 21, 529.	1.3	3
123	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <i>Virus Evolution</i> , 2021, 7, veab057.	2.2	2
124	Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose. <i>Npj Vaccines</i> , 2022, 7, 12.	2.9	2
125	A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 24, 100484.	1.3	1
126	The emergence of a South-South and Triangular Cooperation approach to vaccine development. <i>Journal of Global Health Science</i> , 2021, 3, .	1.7	0

#	ARTICLE	IF	CITATIONS
127	Public Health Value of a Hypothetical Pneumococcal Conjugate Vaccine (PCV) Introduction: A Case Study. <i>Vaccines</i> , 2022, 10, 950.	2.1	0